论文部分内容阅读
目的研究熊去氧胆酸在乙型肝炎肝硬化治疗中的应用价值。方法选取我院2013年4月至2015年4月收治的90例乙型肝炎肝硬化患者的临床资料,将患者随机分为两个组,分别为观察组、对照组,每组45例,对照组给予还原型谷胱甘肽与茵栀黄联合治疗,观察组采用还原型谷胱甘肽与熊去氧胆酸联合治疗,比较两组患者治疗8周后的治疗效果与肝功能指标复常率。结果 1观察组治疗有效率为95.56%,对照组治疗有效率为93.33%,对比无统计学意义(P>0.05)。2观察组的γ谷氨酸转肽酶、碱性磷酸酶指标复常率均高于对照组,对比有统计学意义(P<0.05)。结论熊去氧胆酸的使用能够使乙型肝炎肝硬化患者的γ谷氨酸转肽酶、碱性磷酸酶指标复常率提升,值得临床推广应用。
Objective To study the application of ursodeoxycholic acid in the treatment of hepatitis B cirrhosis. Methods The clinical data of 90 patients with hepatitis B cirrhosis who were treated in our hospital from April 2013 to April 2015 were selected and randomly divided into two groups: observation group and control group, with 45 cases in each group. Group was given reduced glutathione and Yinzhihuang combined treatment, the observation group using reduced glutathione and ursodeoxycholic acid combination therapy, the treatment of two groups of patients after 8 weeks of treatment and liver function indicators of normal rate. Results 1 Observation group, the effective rate was 95.56%, the control group, the effective rate was 93.33%, no significant difference (P> 0.05). The observation group of γ-glutamic acid transpeptidase, alkaline phosphatase indicators of the normal rate were higher than the control group, the difference was statistically significant (P <0.05). Conclusion The use of ursodeoxycholic acid can improve the recovery rate of γ-GTPase and ALP in patients with hepatitis B cirrhosis, which is worthy of clinical application.